AU2021390552A1 - Peptide receptor radionuclide therapy - Google Patents

Peptide receptor radionuclide therapy Download PDF

Info

Publication number
AU2021390552A1
AU2021390552A1 AU2021390552A AU2021390552A AU2021390552A1 AU 2021390552 A1 AU2021390552 A1 AU 2021390552A1 AU 2021390552 A AU2021390552 A AU 2021390552A AU 2021390552 A AU2021390552 A AU 2021390552A AU 2021390552 A1 AU2021390552 A1 AU 2021390552A1
Authority
AU
Australia
Prior art keywords
conjugate
peptide
peg
peg moiety
mci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021390552A
Other languages
English (en)
Other versions
AU2021390552A9 (en
Inventor
Julie L. SUTCLIFFE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California, San Diego filed Critical University of California Berkeley
Publication of AU2021390552A1 publication Critical patent/AU2021390552A1/en
Publication of AU2021390552A9 publication Critical patent/AU2021390552A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021390552A 2020-12-04 2021-12-03 Peptide receptor radionuclide therapy Pending AU2021390552A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063121762P 2020-12-04 2020-12-04
US63/121,762 2020-12-04
PCT/US2021/061886 WO2022120226A1 (en) 2020-12-04 2021-12-03 Peptide receptor radionuclide therapy

Publications (2)

Publication Number Publication Date
AU2021390552A1 true AU2021390552A1 (en) 2023-06-29
AU2021390552A9 AU2021390552A9 (en) 2024-06-20

Family

ID=81853616

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021390552A Pending AU2021390552A1 (en) 2020-12-04 2021-12-03 Peptide receptor radionuclide therapy

Country Status (9)

Country Link
US (1) US12649008B2 (cg-RX-API-DMAC7.html)
EP (1) EP4255891A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023552383A (cg-RX-API-DMAC7.html)
KR (1) KR20230117581A (cg-RX-API-DMAC7.html)
CN (1) CN116829541A (cg-RX-API-DMAC7.html)
AU (1) AU2021390552A1 (cg-RX-API-DMAC7.html)
CA (1) CA3203175A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023006483A (cg-RX-API-DMAC7.html)
WO (1) WO2022120226A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2025211123A1 (en) 2024-01-26 2026-08-13 The Regents Of The University Of California Peptide receptor radionuclide therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO881077L (no) * 1987-03-11 1988-09-12 Univ Michigan Kjemo-radio-immuno-konjugater.
AU2008230771B2 (en) * 2007-03-27 2014-05-08 Radiomedix Inc. Compositions for targeted imaging and therapy
WO2010047839A1 (en) * 2008-10-25 2010-04-29 Aura Biosciences Modified plant virus particles and uses therefor
WO2011082191A1 (en) * 2009-12-30 2011-07-07 Ge Healthcare Limited Method of using a 99mtc-labelled injection rgd compound and a [18f]-labelled rgd injection compound in external beam radiotherapy planning
WO2015160770A1 (en) 2014-04-15 2015-10-22 The Regents Of The University Of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof
CN109563135B (zh) 2016-06-13 2024-01-23 加利福尼亚大学董事会 α(V)β(6)整合素结合肽及其使用方法
CN109982998A (zh) 2016-11-23 2019-07-05 癌靶技术有限责任公司 白蛋白结合psma抑制剂
GB201706472D0 (en) * 2017-04-24 2017-06-07 Cancer Res Tech Ltd Tumour-targeting peptide variants
US11478558B2 (en) * 2017-05-30 2022-10-25 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
CN109091683B (zh) * 2018-08-10 2019-10-18 北京大学 一种用于整合素αvβ6靶向的环状多肽放射性药物及其制备方法
EP3846858A4 (en) 2018-09-07 2022-10-19 The Regents of the University of California ALPHA-(V)BETA(6)INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF
WO2021226432A2 (en) 2020-05-08 2021-11-11 The Regents Of The University Of California Methods of detecting and treating lung damage in respiratory-related viral infections

Also Published As

Publication number Publication date
US20240131206A1 (en) 2024-04-25
CN116829541A (zh) 2023-09-29
MX2023006483A (es) 2023-07-20
KR20230117581A (ko) 2023-08-08
WO2022120226A1 (en) 2022-06-09
CA3203175A1 (en) 2022-06-09
US12649008B2 (en) 2026-06-09
EP4255891A1 (en) 2023-10-11
JP2023552383A (ja) 2023-12-15
EP4255891A4 (en) 2026-03-18
AU2021390552A9 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
JP6997135B2 (ja) Grpr陽性ガンの検出、診断及び治療のためのgrprアンタゴニスト
Chen et al. Integrin αβ3-targeted imaging of lung cancer
EP3766893B1 (en) 177lu-dota-hynic-ipsma as a therapeutic radiopharmaceutical targeting prostate-specific membrane antigen
US12605447B2 (en) Stable formulations for radionuclide complexes
US8986651B2 (en) Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
KR102934560B1 (ko) 신장 보호 물질로서의 파라-아미노히푸르산(pah)
KR20190094160A (ko) 방사선 요법 및 진단 영상용 제형
WO2011005380A2 (en) Arg-gly-asp-conjugated alpha-melanocyte stimulating hormone hybrid peptide for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
Chen et al. In vivo examination of 188Re (I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer
US20240131206A1 (en) Peptide receptor radionuclide therapy
Prasanphanich et al. The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals
Xie et al. Novel 99mTc radiolabeled folate complexes with PEG linkers for FR-positive tumor imaging: Synthesis and biological evaluation
US20240342322A1 (en) Netrin-1 detection, companion test and therapy based on radiations
JP2024500829A (ja) 治療診断剤として使用するための放射性標識α-Vβ-3及び/又はα-Vβ-5インテグリンアンタゴニスト
HK40103039A (en) Peptide receptor radionuclide therapy
WO2025160502A1 (en) Peptide receptor radionuclide therapy
Ahmad The Use of Bioorthogonal Chemistry to Create 99mTc and Micelle-based Diagnostic Agents
WO2024206972A1 (en) Compounds and combinations for diagnosing and treating melanoma and methods related to the same
WO2026083399A1 (en) Conjugates and use of same for theranostics
Däpp PEGylation: a strategy to improve the diagnosis and therapy relevant pharmacokinetic properties of bombesin analogues for targeting GRP receptor-positive tumours
JP2015083546A (ja) 癌の原発巣・骨転移の検査・治療用放射性標識薬剤

Legal Events

Date Code Title Description
SREP Specification republished